Please upgrade your browser.
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC)
Tumor gene expression may impact prognosis following surgery for early stage ccRCC. Genomic analysis may also aid in understanding disease biology.
This novel immunotherapy has demonstrated antitumor activity in multiple tumor types (metastatic melanoma, renal cell cancer and non-Hodgkin's lymphoma) as a single agent and in combination with other therapies.
Long-term sorafenib safety profile in > 700 patients with renal cell carcinoma treated for 12 to 42 months.
Redectane(R) Meets Both Endpoints Specificity And Sensitivity With Superiority Over CT In Its Pivotal Phase III Trial
The aim of the Phase III-REDECT study was to determine whether the combination of REDECTANE® with positron emission tomography (PET) and computer tomography (CT) versus the standard use of CT alone could improve the diagnosis of renal masses. Sensitivity and specificity were the defined endpoints of the study.
Leptomeningeal Carcinomatosis From Renal Cell Cancer: Treatment Attempt With Radiation And Sunitinib
This case illustrates important issues around both biological behaviour and treatment approaches in metastatic renal cell cancer.
The authors are reporting a unique case of papillary RCC with cutaneous metastases diagnosed at their institution.
Use of Tumor Necrosis FactorAlpha-coated Gold Nanoparticles to Enhance Radiofrequency Ablation in a Translational Model of Renal Tumors
The authors have demonstrated the efficacy of CYT6091 in enhancing RFA in a translational kidney tumor model.
Although the prognosis of patients with pT1a stage renal cell carcinoma (RCC) is generally good, some of these patients show distant metastasis. In this study, we intended to identify the perioperative and pathologic prognostic factors for patients with pT1a stage RCC.
By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.
The results show that critical properties of ANYARA (naptumomab estafenatox), such as tumor reactivity and therapeutic window were improved.
|Powered by NeonCRM|